NCT07324473
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality, China
Clinical trial condition
Resistance to Immunotherapy
Explore clinical trials studying Resistance to Immunotherapy. Study availability and eligibility vary by location and protocol.
4 public trials
0 recruiting studies
Resistance to Immunotherapy trial results
Not Yet Recruiting
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
NCT07022301
- Conditions
- Resistance to Immunotherapy, Small Cell Lung Cancer Extensive Stage
- Locations
-
Not specified
Not Yet Recruiting
PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
NCT07014215
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
- Locations
-
Not specified
NCT06076135
- Conditions
- Immune Checkpoint Blockade, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +6 more
- Locations
-
- Cancer Hospital, Shantou University Medical College Shantou, Guangdong, China